Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2015; 36(01): 38-42
DOI: 10.4103/0971-5851.151781
ORIGINAL ARTICLE

Neoadjuvant chemotherapy in advanced epithelial ovarian cancer: A survival study

Upasana Baruah
Department of Gynaecologic Oncology, Dr. B. Borooah Cancer Institute (RCC), Guwahati, Assam, India
,
Debabrata Barmon
Department of Gynaecologic Oncology, Dr. B. Borooah Cancer Institute (RCC), Guwahati, Assam, India
,
Amal Chandra Kataki
Department of Gynaecologic Oncology, Dr. B. Borooah Cancer Institute (RCC), Guwahati, Assam, India
,
Pankaj Deka
Department of Gynaecologic Oncology, Dr. B. Borooah Cancer Institute (RCC), Guwahati, Assam, India
,
Munlima Hazarika
Department of Medical Oncology, Dr. B. Borooah Cancer Institute (RCC), Guwahati, Assam, India
,
Bhargab J. Saikia
Department of Medical Oncology, Dr. B. Borooah Cancer Institute (RCC), Guwahati, Assam, India
› Author Affiliations
› Further Information
  PDF Download Permissions and Reprints

Abstract

Context: Patients with advanced ovarian cancer have a poor prognosis in spite of the best possible care. Primary debulking surgery has been the standard of care in advanced ovarian cancer; however, it is associated with high mortality and morbidity rates as shown in various studies. Several studies have discussed the benefit of neoadjuvant chemotherapy in patients with advanced ovarian cancer. Aims: This study aims to evaluate the survival statistics of the patients who have been managed with interval debulking surgery (IDS) from January 2007 to December 2009. Materials and Methods: During the period from January 2007 to December 2009, a retrospective analysis of 104 patients who underwent IDS for stage IIIC or IV advanced epithelial ovarian cancer at our institute were selected for the study. IDS was attempted after three to five courses of chemotherapy with paclitaxal (175 mg/m 2 ) and carboplatin (5-6 of area under curve). Overall survival (OS) and progression free survival (PFS) were compared with results of primary debulking study from existing literature. OS and PFS rates were estimated by means of the Kaplan-Meier method. Results were statistically analyzed by IBM SPSS Statistics 19. Results: The median OS was 26 months and the median PFS was 18 months. In multivariate analysis it was found that both OS and PFS was affected by the stage, and extent of debulking. Conclusions: Neoadjuvant chemotherapy, followed by surgical cytoreduction is a promising treatment strategy for the management of advanced epithelial ovarian cancers.

Keywords

Interval debulking surgery - neoadjuvant chemotherapy - ovarian cancer - primary debulking surgery


Publication History

Article published online:
12 July 2021

© 2015. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Wright JD, Herzog TJ, Powell MA. Morbidity of cytoreductive surgery in the elderly. Am J Obstet Gynecol 2004;190:1398-400.
  • 2 Michel G, De Iaco P, Castaigne D, el-Hassan MJ, Lobreglio R, Lhommé C, et al. Extensive cytoreductive surgery in advanced ovarian carcinoma. Eur J Gynaecol Oncol 1997;18:9-15.
  • 3 Hoskins WJ, McGuire WP, Brady MF, Homesley HD, Creasman WT, Berman M, et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol 1994;170:974-9.
  • 4 Eisenkop SM, Friedman RL, Wang HJ. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: A prospective study. Gynecol Oncol 1998;69:103-8.
  • 5 Guidozzi F, Ball JH. Extensive primary cytoreductive surgery for advanced epithelial ovarian cancer. Gynecol Oncol 1994;53:326-30.
  • 6 Shimada M, Kigawa J, Minagawa Y, Irie T, Takahashi M, Terakawa N. Significance of cytoreductive surgery including bowel resection for patients with advanced ovarian cancer. Am J Clin Oncol 1999;22:481-4.
  • 7 Donato D, Angelides A, Irani H, Penalver M, Averette H. Infectious complications after gastrointestinal surgery in patients with ovarian carcinoma and malignant ascites. Gynecol Oncol 1992;44:40-7.
  • 8 Chi DS, Zivanovic O, Levinson KL, Kolev V, Huh J, Dottino J, et al. The incidence of major complications after the performance of extensive upper abdominal surgical procedures during primary cytoreduction of advanced ovarian, tubal, and peritoneal carcinomas. Gynecol Oncol 2010;119:38-42.
  • 9 Kayikçioglu F, Köse MF, Boran N, Caliskan E, Tulunay G. Neoadjuvant chemotherapy or primary surgery in advanced epithelial ovarian carcinoma. Int J Gynecol Cancer 2001;11:466-70.
  • 10 Kuhn W, Rutke S, Späthe K, Schmalfeldt B, Florack G, von Hundelshausen B, et al. Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics Stage IIIC ovarian carcinoma. Cancer 2001;92:2585-91.
  • 11 Ansquer Y, Leblanc E, Clough K, Morice P, Dauplat J, Mathevet P, et al. Neoadjuvant chemotherapy for unresectable ovarian carcinoma: A French multicenter study. Cancer 2001;91:2329-34.
  • 12 Redman CW, Warwick J, Luesley DM, Varma R, Lawton FG, Blackledge GR. Intervention debulking surgery in advanced epithelial ovarian cancer. Br J Obstet Gynaecol 1994;101:142-6.
  • 13 van der Burg ME, van Lent M, Buyse M, Kobierska A, Colombo N, Favalli G, et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med 1995;332:629-34.
  • 14 Vergote I, Tropé CG, Amant F, Kristensen GB, Ehlen T, Johnson N, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 2010;363:943-53.
  • 15 Comparisions of Age Adjusted Incidence Rates (AAR) of all PBCRs of OVARY (ICD-10: C56). In: Three Year Report of Population Based Cancer Registries 2009-2011. Bangalore: NCDIR-NCRP (ICMR) Publication; 2013. p. 56.
  • 16 Heintz AP, Odicino F, Maisonneuve P, Quinn MA, Benedet JL, Creasman WT, et al. Carcinoma of the ovary. FIGO 26 th annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet 2006;95:S161-92.
  • 17 Laky B, Janda M, Bauer J, Vavra C, Cleghorn G, Obermair A. Malnutrition among gynaecological cancer patients. Eur J Clin Nutr 2007;61:642-6.
  • 18 Chellan R, Paul L. Prevalence of iron-deficiency anaemia in India: Results from a large nationwide survey. J Popul Soc Stud 2010;19:59-80.
  • 19 Di Maio M, Pisano C, Tambaro R, Greggi S, Casella G, Laurelli G, et al. The prognostic role of pre-chemotherapy hemoglobin level in patients with ovarian cancer. Front Biosci 2006;11:1585-90.
  • 20 Kumar L, Hariprasad R, Kumar S, Bhatla N, Thulkar S, Shukla NK. Neo-adjuvant chemotherapy in advanced epithelial ovarian cancer (EOC): A prospective, randomized study. Indian J Med Paediatr Oncol 2009;30:15.
  • 21 Kehoe S, Hook J, Nankivell M, Gordon CJ, Henry CK, Tito L, et al. Chemotherapy or Upfront Surgery for Newly Diagnosed Advanced Ovarian Cancer: Results from the MRC CHORUS Trial 2013 ASCO Annual Meeting. Abstract 5500. Presented; June 1, 2013.
  • 22 Morice P, Brehier-Ollive D, Rey A, Atallah D, Lhommé C, Pautier P, et al. Results of interval debulking surgery in advanced stage ovarian cancer: An exposed-non-exposed study. Ann Oncol 2003;14:74-7.
  • 23 Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: A meta-analysis. J Clin Oncol 2002;20:1248-59.
  • 24 du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: By the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d′Investigateurs Nationaux Pour les Etudes des Cancers de l′Ovaire (GINECO). Cancer 2009;115:1234-44.
  • 25 Bonnefoi H, A′Hern RP, Fisher C, Macfarlane V, Barton D, Blake P, et al. Natural history of stage IV epithelial ovarian cancer. J Clin Oncol 1999;17:767-75.